Limits...
Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo.

You Q, Yao Y, Zhang Y, Fu S, Du M, Zhang G - Mol Med Rep (2015)

Bottom Line: The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo.AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed.It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

ABSTRACT
The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo. AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed. The plasmid was stably transfected into the AF‑MSCs and the cells were intravenously injected into ovarian cancer nude mice models. Following stable transfection of the vector, tumor formation, and the expression and activity of hIL‑2 were investigated, and microscopic pathological examinations of the tumor were performed. It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs. Following stable transfection, this type of stem cell is able to successfully transport the therapeutic gene, IL-2, migrate to the ovarian cancer tumor site to secrete the functional IL-2 and treat the tumor. Thus, AF-MSCs may serve as transporters for therapeutic genes targeting ovarian tumor sites and, therefore, be involved in the treatment of tumors.

Show MeSH

Related in: MedlinePlus

Expression of the hIL-2 gene following transfection into amniotic fluid mesenchymal stem cells. OD, optical density; hIL-2, human interleukin-2.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581758&req=5

f10-mmr-12-04-4859: Expression of the hIL-2 gene following transfection into amniotic fluid mesenchymal stem cells. OD, optical density; hIL-2, human interleukin-2.

Mentions: A standard substance dilution was used and the optical density (OD) value was measured at 450 nm. The standard curve is shown in Fig. 10. The OD value of the clear supernatant of the recombinant plasmid-transfected AF-MSCs at 450 nm was 1.103, while that of the untransfected cells was 0.052. The OD value of the tested sample was more than five times higher than that of the negative control, therefore the result was positive according to the kit instructions. The following formula was used: y=ax2+bx+c as well as the standard curve, and the hIL-2 concentration in the treated sample was found to be 17.258 pg/ml.


Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo.

You Q, Yao Y, Zhang Y, Fu S, Du M, Zhang G - Mol Med Rep (2015)

Expression of the hIL-2 gene following transfection into amniotic fluid mesenchymal stem cells. OD, optical density; hIL-2, human interleukin-2.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581758&req=5

f10-mmr-12-04-4859: Expression of the hIL-2 gene following transfection into amniotic fluid mesenchymal stem cells. OD, optical density; hIL-2, human interleukin-2.
Mentions: A standard substance dilution was used and the optical density (OD) value was measured at 450 nm. The standard curve is shown in Fig. 10. The OD value of the clear supernatant of the recombinant plasmid-transfected AF-MSCs at 450 nm was 1.103, while that of the untransfected cells was 0.052. The OD value of the tested sample was more than five times higher than that of the negative control, therefore the result was positive according to the kit instructions. The following formula was used: y=ax2+bx+c as well as the standard curve, and the hIL-2 concentration in the treated sample was found to be 17.258 pg/ml.

Bottom Line: The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo.AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed.It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

ABSTRACT
The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo. AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed. The plasmid was stably transfected into the AF‑MSCs and the cells were intravenously injected into ovarian cancer nude mice models. Following stable transfection of the vector, tumor formation, and the expression and activity of hIL‑2 were investigated, and microscopic pathological examinations of the tumor were performed. It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs. Following stable transfection, this type of stem cell is able to successfully transport the therapeutic gene, IL-2, migrate to the ovarian cancer tumor site to secrete the functional IL-2 and treat the tumor. Thus, AF-MSCs may serve as transporters for therapeutic genes targeting ovarian tumor sites and, therefore, be involved in the treatment of tumors.

Show MeSH
Related in: MedlinePlus